Corporate News Blog - Magellan Health Announces the Receipt of All Necessary Regulatory Approvals for Acquiring Senior Whole Health

LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Magellan Health, Inc. (NASDAQ: MGLN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MGLN. The Company announced on October 09, 2017, declared the receipt of all necessary regulatory approvals regarding its agreement to acquire Senior Whole Health (SWH). The acquisition is likely to close on or before December 31, 2017, which was earlier expected to close by the end of Q1 2018. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MGLN. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=MGLN

Acquisition Makes Sense from both Strategic and Financial Perspective

Barry M. Smith, Chairman and Chief Executive Officer of Magellan Health, stated that the receipt of all necessary approvals around this transaction is illustrative of both Magellan's and SWH's sound business strategy and execution concerning the acquisition. Barry added that as a leader in managing chronic and specialty populations, this acquisition makes sense from both a strategic and a financial perspective.

Magellan Health Signed an Agreement to Acquire Senior Whole Health in July 2017

News releases suggest that on July 13, 2017, Magellan Health entered into a definitive agreement to acquire SWH. The acquisition would provide Magellan with an opportunity to expand into the Massachusetts Senior Care Options program and New York City's managed long-term care market. The Company plans to leverage SWH's sound, culturally competent clinical model and expertise.

Under the terms of the agreement, Magellan would acquire SWH for approximately $400 million cash, inclusive of a $10 million contingent payment. The Company anticipated paying the purchase price from the proceeds of new debt offerings. The transaction was subject to certain state and federal regulatory approvals as well as standard closing conditions and customary approvals required under the Hart-Scott-Rodino Antitrust Improvements Act.

Magellan Rx Management Collaborates with Health New England to Launch New Hemophilia Management Program

On August 01, 2017, Magellan Health's pharmacy benefit management division, Magellan Rx Management, launched a hemophilia management program in collaboration with Health New England, a non-profit health plan serving the commercial, Medicaid, and Medicare markets. The program is targeted to manage hemophilia utilization on both the pharmacy and medical benefits and aims to improve overall quality of care while reducing unnecessary costs.